We are Committed to being a Collaborative Platform for Innovative Biotech Companies from around the World.
Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.
An Innovative Idea is All You Need
Our leading CRO platform is productive and efficient and it enables both quick and quality drug candidate discovery
Average time to invest: 2 months; Introductions for later-stage funding and financial advice
Business Partners Venture Advisors
Assistance in procuring internal or external resources
“Back-office” support (HR, Accounting, Procurement, BD, Financing, etc.)
We invest in some of the most innovative founders to build a unique portfolio covering a wide range of indications and drug types.
Read the most up to date information about us and our partners.
A Cradle for Promising Biotech Companies from around the World
Sam Cooper founded Phenomic AI in 2017 alongside Oren Kraus, as an early stage biotech company seeking to commercialise AI appr...
The cradle for promising biotechnology startups all around the world.
The first Claudin 18.2/PD-L1 bispecific antibody drug accepted by NMPA.
Viva Biotech will give full play to its capabilities and advantages as a one-stop comprehensive service platform for drug R&D.
Viva Biotech will cooperate with AlphaMa to provide clients AI-based DNA coding compound library screening technology.